CDT Equity Inc
Company Profile
Business description
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company’s current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto’s Thyroiditis, preterm labor, and renal transplant rejection. The Company’s development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Contact
4581 Tamiami Trail North
Suite 200
NaplesFL34103
USAT: +1 646 491-9132
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
stocks
How I lost all my savings through a poor investment decision
stocks
Chart of the Week: Morningstar’s forecast for CSL’s future
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,063.40 | 33.90 | 0.38% |
| CAC 40 | 7,767.88 | 59.57 | -0.76% |
| DAX 40 | 23,428.08 | 238.73 | -1.01% |
| Dow JONES (US) | 46,121.28 | 171.50 | -0.37% |
| FTSE 100 | 9,216.03 | 34.40 | -0.37% |
| HKSE | 26,484.68 | 33.97 | -0.13% |
| NASDAQ | 22,497.86 | 75.62 | -0.33% |
| Nikkei 225 | 45,754.93 | 124.62 | 0.27% |
| NZX 50 Index | 13,153.79 | 27.52 | -0.21% |
| S&P 500 | 6,637.97 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,773.00 | 35.10 | 0.40% |
| SSE Composite Index | 3,853.30 | 0.34 | -0.01% |